Background {#Sec1}
==========

Medication prescribing for the elderly is a complex task that requires special care and increased patient monitoring, while appropriate medications are vital for keeping elderly patients healthy, especially those with multiple diseases who use polypharmacy. Japan is known as the most aged country with 26.5% of the population older than 65 \[[@CR1]\]. Therefore, a regulatory meeting was established in 2017 to discuss appropriate prescribing and medication use in the elderly and ensure adaptability to the changing medical status of patients \[[@CR2]\]. Furthermore, this strategy is expected to reduce the side effects and polypharmacy and ensure reasonable medical costs \[[@CR2]\]. Japan has been releasing new drugs to the world, and its regulatory authorities and pharmaceutical companies are expected to provide enough information and formulate precautions for the use of drugs in the elderly. However, since clinical trials mostly exclude the elderly, clinical information for this demographic is scarce for most new drugs, studies are eagerly anticipated, which is true in every country and region.

To aid physicians to prescribe appropriately, the Japan Geriatric Society (JGS) first published guidelines for safe pharmacotherapy in the elderly, and a list of potentially inappropriate medication uses in 2005 \[[@CR3]\], which is recognized as the Japanese version of the Beers criteria \[[@CR4]\]. It was updated in 2015, providing the Screening Tool for Older Persons' Appropriate Prescriptions for the Japanese (STOPP-J) for drugs to be prescribed with special caution and drugs to be considered for treatment \[[@CR5]\]. Ahead of this, in Europe, the Screening Tool of Older Persons' potentially inappropriate Prescription (STOPP) \[[@CR6], [@CR7]\], proposed by the Ireland study group, is reported as a useful guide for identifying potentially inappropriate medications, particularly for hospital inpatients \[[@CR8]\].

Recent evolutions in medical informatics and computerization have enabled researchers to use various databases and analytical tools in their studies. Studies using the databases of regulatory authorities, insurance claims, and medical records, as well as patients' reports have become popular in public health disciplines and drug development phases recently as well as post-marketing phase. However, there are still challenges associated with the methods of collection, coding, and analysis of data for assessing the accuracy of medication use. The use of identical names or a systematic code for drugs enhances the efficiency of research with large-scale databases \[[@CR9]\]. However, coding of medication data depends on the regulatory system, which varies between countries. For example, the National Drug Code in the US (<https://www.fda.gov/Drugs/InformationOnDrugs/ucm142438.htm.>) differs from the BNF codes (<https://data.gov.uk/dataset/176ae264-2484-4afe-a297-d51798eb8228/resource/bac33489-b3dc-47ec-b688-da9cf40e25bd>) in the UK. For research on medicine use in the elderly, the AGS Beers criteria \[[@CR4]\], STOPP/START \[[@CR7]\], and JGS guidelines \[[@CR5]\] have been used. However, these guidelines mainly provide drug categories and medication considerations, which lack consistency (Table [1](#Tab1){ref-type="table"}). In addition, they do not specifically define molecular entities, so that researchers have to select drug substances to be studied. Therefore, variation often occurs when using databases to investigate drug use. To facilitate computerized work with databases, Groot et al. \[[@CR8]\] proposed a uniform coding for drugs approved in the Netherlands, compliant with the STOPP/START. On the other hand, Japan has several drug-coding systems, depending on the regulatory objective, such as those for labeling information, reimbursement of medical fees, and a third for logistics, but they are solely for domestic use. A variety of proprietary databases is currently available in Japan, and medical terms are mostly compared between them using the International Classification of Diseases (ICD) \[[@CR10]\] or the Medical Dictionary for Regulatory Activities (MedDRA) \[[@CR11]\], which are internationally recognized in pharmacoepidemiological studies. Unfortunately, due to nationally defined drug coding based on approval, the indications differ, and the classification of medication data may not be consistent across databases. Furthermore, additional efforts for drug identification and matching are necessary when coding systems are different. This process could introduce mismatching and misinterpretation flaws into studies using multiple databases. Therefore, it would be worthwhile to standardize drug codes for international use, e.g., global pharmacovigilance, as the aforementioned Dutch group did by identifying STOPP/START drugs at the substance level and using international coding systems \[[@CR8]\]. However, while a local version of the Beers criteria and STOPP/START has been proposed in Japan \[[@CR12], [@CR13]\], no guidelines have been presented on how to encode medications. In this paper, we present a proposal to encode drugs in JGS medication guidelines using the Anatomical Therapeutic Chemical Classification System (ATC) \[[@CR14]\], supporting the extraction and validity of the medication use data.Table 1Characteristics of pharmacotherapy criteria for older adultsAGS Beer's criteria 2015 ^1)^STOPP/START v2 2015 ^2)^JGS STOPP-J 2015 ^3)^Latest version DevelopedAGSStudy group at University College CorkJGSOriginal version (year, developer)1991, Dr. Beers2008, Study group at University College Cork2005, JGSTarget populationUnited States; 65 and older; Ambulatory, acute, and institutionalized settingsEurope-wide prescribing practices;65 and older; in most clinical settingsJapan; 75 and older; 74 and younger with frailty; 65 and older in need of nursing care; chronic treatmentTherapeutic category / drug26 potentially inappropriate medication (PIM)\
12 PIM due to drug-disease/ drug-syndrome interactions\
5 PIM to be used with caution\
10 PIM non-anti-infective drug-drug interactions that should be avoided in older adults80 criteria in STOPP\
34 criteria in START29 groups for drugs to be prescribed with special caution\
8 groups for drugs to consider startingRemarksSupplement information: "Quality of evidence" and "Strength of Recommendation"For adverse drug events prevention and cost reductionSupplement information: "Quality of evidence" and "Strength of Recommendation"*Abbreviations*:AGS: American Geriatric SocietyJGS: Japan Geriatric SocietyPIM: Potentially Inappropriate Medication use in older adultsSTOPP: Screening Tool of Older People's potentially inappropriate PrescriptionsSTART: Screening Tool to Alert doctors to Right TreatmentSTOPP-J: Screening Tool for Older Persons' Appropriate Prescriptions for Japanese^1)^American Geriatrics Society. 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015;63:2227--2246^2)^O'Mahony D, O'Sullivan D, Byrne S, O'Connor M, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213--218^3)^Kojima T, Mizukami K, Tomita N, Arai H, Ohrui T, Eto M, et al. Screening Tool for Older Persons' Appropriate Prescriptions for Japanese: Report of the Japan Geriatrics Society Working Group on"Guidelines for medical treatment and its safety in the elderly." Geriatrics Gerontology Int. 2016;16:983--1001

Methods {#Sec2}
=======

Process for listing drug substances {#Sec3}
-----------------------------------

This study was set up voluntarily by three physicians (Akishita, Kojima, and Ishii) and two pharmacists (Akazawa and Nomura) who have experience with studies on drug use in the elderly, using both clinical observations and databases. The STOPP-J 2015 developed by the JGS through systematic review, repeated group discussion, and review by the related academic societies, followed by public consultation \[[@CR15]\], was the basis for this study. This JGS tool for medications for older persons does not include details on drug dosage, frequency, or duration of administration, but rather includes drug categories or names. The first step involved drafting a list of approved proprietary names based on JGS guidelines with the support of the Japan Pharmaceutical Information Center (JAPIC), an organization that provides drug information and codes to the Ministry of Health, Labour and Welfare, and pharmaceutical companies. JAPIC provided the English and Japanese names of medicinal substances, supervised by Akazawa and Nomura. The National Health Insurance Drug Price List as of February 2017 \[[@CR16]\] was referenced for substance names in Japanese. They included all relevant active substances approved in Japan, which were grouped into specific categories, e.g., the statin category included atorvastatin, simvastatin, pitavastatin, pravastatin, fluvastatin, and rosuvastatin.

In the second step, the physicians, Kojima and Ishii, reviewed the drafted drug names in parallel from the perspectives of clinical treatment of the elderly, supervised by Akishita to reach a consensus. Since the JGS guidelines suggest controlling long-term medication for older persons to avoid untoward systemic adverse events occurring in any case where a drug is used or unused, external drugs and injections were excluded, except for self-injection. Simultaneously, the pharmacists matched the Japanese drug names with the national price list and the English drug names with ATC codes according to pharmacological criteria. Yonekawa helped encoding work. All possible oral indications were considered. Table [2](#Tab2){ref-type="table"} shows the criteria used to choose substances, categories, and codes.Table 2Procedures and concepts for listing drugs and codesListing drugs- Listed JGS substances were limited to those approved as medicinal product for oral use in Japan, except insulin.\
- Listed JGS substances were prescribed for long-term use in general.\
- If a combination drug is comprised with more than one of listed therapeutic category, combinations were presented in Table [5](#Tab5){ref-type="table"}.Coding with ATC- If ATC codes at the 5th level cannot be directly matched to the substance, an alternate 4th level code is proposed by searching online \[[@CR1]\].\
- The 5th level ATC code is proposed when it is available for the combination, otherwise ATC codes are searched for each substance.\
- ATC codes for topical use were excludedCoding with Japan code- Some vaccines are not available because vaccine is not covered by the pricing list for the national health insurance but by other public support.\
- The pricing list is available for medicinal products currently in the market.*Abbreviations:*JGS: Japan Geriatric SocietyATC: Anatomical Therapeutic Chemical^1)^WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2017. [https://www.whocc.no/atc_ddd_index/](https://www.whocc.no/atc_ddd_index) Accessed: Accessed 5 June 2017

Drug classification systems {#Sec4}
---------------------------

There are two major global drug classification systems; the Anatomical Therapeutic Classification by the European Pharmaceutical Market Research Association (EPhMRA) \[[@CR17]\] and the ATC created by the World Health Organization (WHO) Collaborating Centre for Drug Statistics \[[@CR14]\]. Our study used the WHO ATC classification, which has codes at the substance level known as the 5th level.

In Japan, several drug-coding systems exist. The Japan standard commodity classification includes classes for drugs, which appear similar to the 3rd level of the ATC. However, it should be used with caution since it has not been updated since 1990 and, therefore, numerous new drugs are coded as "others." Based on this system, the National Health Insurance Drug Price List \[[@CR16], [@CR18]\] provides 7-digit drug codes at substance level, similar to the ATC 5th level, and 12-digit codes at the product level. In contrast with the ATC process, we extracted the code using the first 7-digit  numeric code from the 12-digit alphanumeric code to represent the substance level.

The selected drugs and the corresponding codes, proposed first by Nomura and Yonekawa, were compared with those formulated separately by the Japanese system vendor, Data Horizon Corporation (<https://www.dhorizon.co.jp>). Then, the differences were checked and returned to both the authors and the corporation to reach a consensus.

Results {#Sec5}
=======

The drug list is presented in Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, and [5](#Tab5){ref-type="table"}. Of the 236 encoded drug substances, 197 matched the 5th level of the ATC, along with 10 of 26 combinations. No ATC was available at the 5th level for 39 substances and, therefore, they were identified as 4th level substances. If multiple ATCs at the 5th level were available for one substance, the best pharmacological match or the indication-matched ATC was selected and presented with the rest of the possible ATCs. These lists are available as a PDF and spreadsheet at <http://docrd.jp/ftp_up/STOPP-J%20List.pdf> and <http://docrd.jp/ftp_up/STOPP-J%20List.xlsx>, and also on the JGS web page for the STOPP-J in Japanese, <http://www.jpn-geriat-soc.or.jp/tool/pdf/list_02.pdf> and <http://www.jpn-geriat-soc.or.jp/tool/xls/list_03.xlsx>. Since the JGS's list was prepared as a support tool for daily medical practices, medicines rarely used or withdrawn were excluded from our list. Medicines used for short-term treatments were also excluded. The STOPP-J shows all Insulin products as drugs to be prescribed with special caution, however, if describing more accurately it recommends prescribers consider to stop sliding scale administration. This indicates that insulins can be prescribed and, therefore, they are excluded from coding.Table 3Proposal for drug coding of "List of drugs to be prescribed with special caution" ^1)^Therapeutic category/JAN English nameJapan ^2)^ATC^3)^Nervous system: Overall antipsychotic drugs - Antipsychotic drugsAripiprazole Hydrate1179045N05AX12Asenapine Maleate1179056N05AH05Blonanserin1179048N05AXBromperidol1179028N05 AD06Chlorpromazine Hydrochloride1171001N05AA01Chlorpromazine Phenolphthalinate1171005N05AA01Clocapramine Hydrochloride Hydrate1179030N05AXClozapine1179049N05AH02Fluphenazine Maleate1172009N05AB02Haloperidol1179020N05 AD01Levomepromazine Maleate1172014N05AA02Mosapramine Hydrochloride1179035N05AX10Nemonapride1179036N05ALOlanzapine1179044N05AH03Oxypertine1179011N05AE01Paliperidone1179053N05AX13Perphenazine1172006\
1172007N05AB03Perphenazine Fendizoate1172004N05AB03Perphenazine Maleate1172013N05AB03Perospirone Hydrochloride Hydrate1179043N05AXPimozide1179022N05AG02Pipamperone Hydrochloride1179006N05 AD05Prochlorperazine Maleate1172010N05AB04Propericiazine (Periciazine)1172005N05 AC01Quetiapine Fumarate1179042N05AH04Risperidone1179038N05AX08Spiperone1179015N05 ADSulpiride1179016\
2329009N05AL01Sultopride Hydrochloride1179032N05AL02Tiapride Hydrochloride1190004N05AL03Timiperone1179026N05 ADZotepine1179024N05AX11Combination (see Table [5](#Tab5){ref-type="table"})Nervous system: BenzodiazepinesAlprazolam1124023N05BA12Bromazepam1124020N05BA08Brotizolam1124009N05CD09Chlordiazepoxide1124028N05BA02Clorazepate Dipotassium1124015N05BA05Clotiazepam1179012N05BA21Cloxazolam1124014N05BA22Diazepam1124017N05BA01Estazolam1124001N05CD04Ethyl Loflazepate1124029N05BA18Etizolam1179025N05BA19Fludiazepam1124019N05BA17Flunitrazepam1124008N05CD03Flurazepam Hydrochloride1124002N05CD01Flutazolam1124024N05BAFlutoprazepam1124027N05BAHaloxazolam1124005N05CDLorazepam1124022N05BA06Lormetazepam1124010N05CD06Medazepam1124021N05BA03Mexazolam1124025N05BANimetazepam1124004N05BANitrazepam1124003N05CD02Oxazolam1124013N05BAQuazepam1124030N05CD10Rilmazafone Hydrochloride Hydrate1129006N05CDTofisopam1124026N05BA23Triazolam1124007N05CD05Nervous system: Non-benzodiazepinesEszopiclone1129010N05CF04Zolpidem Tartrate1129009N05CF02Zopiclone1129007N05CF01Nervous system: Tricyclic antidepressantsAmitriptyline Hydrochloride1179002N06AA09Amoxapine1179001N06AA17Clomipramine Hydrochloride1174002N06AA04Dosulepin Hydrochloride1179027N06AA16Imipramine Hydrochloride1174006N06AA02Lofepramine Hydrochloride1174004N06AA07Nortriptyline Hydrochloride1179004N06AA10Trimipramine Maleate1174005N06AA06Nervous system: Selective serotonin reuptake inhibitor (SSRI)Escitalopram Oxalate1179054N06AB10Fluvoxamine Maleate1179039N06AB08Paroxetine Hydrochloride Hydrate1179041N06AB05Sertraline Hydrochloride1179046N06AB06Nervous system: Antiparkinsonian drugs -- Anticholinergic drugsBiperiden Hydrochloride1162001N04AA02Mazaticol Hydrochloride Hydrate1169004N04AA10Piroheptine Hydrochloride1169003N04AAProfenamine Hibenzate1163002N04AA05Profenamine Hydrochloride1163001N04AA05Promethazine Hydrochloride4413002R06AD02\
D04AA10Promethazine Hibenzate4413002R06AD02\
D04AA10Promethazine Methylenedisalicylate4413002R06AD02\
D04AA10Trihexyphenidyl Hydrochloride1169001\
1169002N04AA01Systemic hormonal preparations, excl. Sex hormones and insulins: Oral corticosteroidsBetamethasone2454004H02AB01Cortisone Acetate2452001H02AB10Dexamethasone2454002D07AB19\
H02AB02Hydrocortisone2452002H02AB09Methylprednisolone2456003H02AB04Prednisolone2456001\
2456002H02AB06Triamcinolone2454003H02AB08Combination (see Table [5](#Tab5){ref-type="table"})Blood and blood forming organs: Antithrombotic drugsAcetylsalicylic acid (Aspirin)1143001\
3399007N02BA01\
B01AC06Apixaban3339004B01AF02Cilostazol3399002B01AC23Clopidogrel Sulfate3399008B01AC04Dabigatran Etexilate Methanesulfonate3339001B01AE07Edoxaban Tosilate Hydrate3339002B01AF03Prasugrel Hydrochloride3399009B01AC22Rivaroxaban3339003B01AF01Ticlopidine Hydrochloride3399001B01AC05Ticagrelor3399011B01AC24Warfarin potassium3332001B01AA03Combination (see Table [5](#Tab5){ref-type="table"})Cardiovascular system: DigitalisDigoxin2113003\
2113004C01AA05Metildigoxin2113005C01AA08Cardiovascular system: High-ceiling diureticsAzosemide2139008C03CABumetanide2139004C03CA02Furosemide2139005C03CA01Piretanide2139007C03CA03Torasemide2139009C03CA04Cardiovascular system: Potassium-sparing agentsEplerenone2149045C03DA04Spironolactone2133001C03DA01Cardiovascular system: Beta blocking agentsAlprenolol Hydrochloride2123002C07AA01Arotinolol Hydrochloride2123014C07AABufetolol Hydrochloride2123006C07AACarteolol Hydrochloride2123005\
2149025C07AA15\
S01ED05Nadolol2123015C07AA12Nipradilol2149021C07AA\
S01EDPindolol2123009\
2149011C07AA03Propranolol Hydrochloride2123008\
2149014C07AA05Cardiovascular system: Alpha1 blocking agentsBunazosin Hydrochloride2149015C02CADoxazosin Mesilate2149026C02CA04Prazosin Hydrochloride2149002C02CA01Terazosin Hydrochloride Hydrate2149023G04CA03Urapidil2149020C02CA06Respiratory system: H~1~ receptor antagonists (1st generation)Alimemazine Tartrate4413003R06AD01Chlorpheniramine Maleate4419001\
4419003R06AB04Clemastine Fumarate4419008R06AA04Cyproheptadine Hydrochloride Hydrate4419005R06AX02D-chlorpheniramine Maleate4419002R06AB04Diphenhidramine4411001R06AA02Homochlorcyclizine Hydrochloride4419006R06AEHydroxyzine Hydrochloride1179005N05BB01Hydroxyzine Pamoate1179019N05BB01Promethazine Hibenzate (relisted)4413002R06AD02Promethazine Hydrochloride (relisted)4413002R06AD02Promethazine Methylenedisalicylate (relisted)4413002R06AD02Combination (see Table [5](#Tab5){ref-type="table"})Alimentary tract and metabolism: H~2~ receptor antagonistsCimetidine2325001A02BA01Famotidine2325003A02BA03Lafutidine2325006A02BA08Nizatidine2325005A02BA04Ranitidine Hydrochloride2325002A02BA02Roxatidine Acetate Hydrochloride2325004A02BA06Alimentary tract and metabolism: Antiemetic agentsMetoclopramide2399004A03FA01Promethazine Hibenzate (relisted)4413002R06AD02\
D04AA10Promethazine Hydrochloride (relisted)4413002R06AD02\
D04AA10Promethazine Methylenedisalicylate (relisted)4413002R06AD02\
D04AA10Alimentary tract and metabolism: Drugs for constipationMagnesium Oxide2344002\
2344009A02AA02\
A06AD02Alimentary tract and metabolism: BiguanidesBuformin Hydrochloride3962001A10BA03Metformin Hydrochloride3962002A10BA02Combination (see Table [5](#Tab5){ref-type="table"})Alimentary tract and metabolism: sulfonylureasAcetohexamide3961001A10BB31Chlorpropamide3961004A10BB02Glibenclamide3961003A10BB01Gliclazide3961007A10BB09Glimepiride3961008A10BB12Glyclopyramide3961002A10BBTolbutamide3961006A10BB03Combination (see Table [5](#Tab5){ref-type="table"})Alimentary tract and metabolism: Alpha glucosidase inhibitorsAcarbose3969003A10BF01Miglitol3969009A10BF02Voglibose3969004A10BF03Combination (see Table [5](#Tab5){ref-type="table"})Alimentary tract and metabolism: ThiazoridinedionesPioglitazone Hydrochloride3969007A10BG03Combination (see Table [5](#Tab5){ref-type="table"})Alimentary tract and metabolism: Sodium-glucose co-transporter 2 (SGLT2) inhibitorsCanagliflozin Hydrate3969022A10BK02Dapagliflozin Propylene Glycolate Hydrate3969019A10BK01Empagliflozin3969023A10BK03Ipragliflozin L-proline3969018A10BKLuseogliflozin Hydrate3969020A10BKTofogliflozin Hydrate3969021A10BKUrologicals: Muscarinic receptor antagonistsFesoterodine Fumarate2590015G04BD11Imidafenacin2590013G04BDOxybutynin Hydrochloride2590005G04BD04Propiverine Hydrochloride2590007G04BD06Solifenacin Succinate2590011G04BD08Tolterodine Tartrate2590012G04BD07Musculo-skeletal system: Non-steroidal antiinflammatory drugs (NSAIDs)Acemetacin1145003M01AB11Amfenac Sodium Hydrate1147006M01ABAmpiroxicam1149030M01 ACAcetylsalicylic acid (Aspirin) (relisted)1143001\
3399007N92BA01\
B01AC06Bucolome1149009M01AXDiclofenac Sodium1147002M01AB05\
S01 BC03\
M02AA15Emorfazone1148004N02BGEtodolac1149032M01AB08Flufenamate Aluminum1141004M01AG03Flurbiprofen1149011M01AE09\
M02AA19Ibuprofen1149001M01AE01Indometacin1145001\
1145002C01EB03\
M01AB01\
M02AA23Indomethacin Farnesil1145005M01AB01Lornoxicam1149036M01 AC05Loxoprofen Sodium Hydrate1149019M01AE\
M02AAMefenamic Acid1141005M01AG01Meloxicam1149035M01 AC06Mofezolac1149033M01AXNabumetone1149027M01AX01Naproxen1149007M01AE02Oxaprozin1149026M01AE12Piroxicam1149017M01 AC01\
M02AA07\
S01 BC06Pranoprofen1149010S01 BC09Proglumetacin Maleate1145004M01AB14Sulindac1149015M01AB02Tiaprofenic Acid1149025M01AE11Tiaramide Hydrochloride1148001N02BGZaltoprofen1149029M01AECombination (See Table [5](#Tab5){ref-type="table"})Japanese version available at <http://www.jpn-geriat-soc.or.jp/tool/xls/list_03.xlsx> or <http://www.jpn-geriat-soc.or.jp/tool/pdf/list_02.pdf>ATC: Anatomical Therapeutic Chemical Classification SystemJAN: Japanese Accepted Names for PharmaceuticalsJapan: the first 7-digit numbers of the code of the Japanese drug price list^1)^Drugs that had been previously approved but do not currently being marketed are excluded. The list includes long-term oral use drugs as a general rule, except self-injection insulin, according to the guidelines (Japan Geriatric Society. Guidelines for Medical Treatment and its Safety in the elderly 2015 (In Japanese). Toyko, Medical View Co., Ltd. 2015)^2)^A different base adduct may or may not require different codes in Japan; hydroxyzine (1179005 for hydrochloride, 1179019 for pamoate) or promethazines (4413002)^3)ATC^ codes for topical use were excluded, e.g. A07EA Corticosteroids acting locally, D04AA Antihistamines for topical use; defined daily dose (DDD) are not available for most of those^4)^The guidelines distinguish sulpiride and sultopride from other antipsychotic drugs^5)^The guidelines distinguish acetyhlsalicylic acid (aspirine) from other antithrombotic drugs^6)^The guidelines distinguish oxybutynin from other muscarinic receptor antagonists^7)^The guidelines does not have metildigoxin (oral), however it is marketed and added to the Table [3](#Tab3){ref-type="table"} from molecular based perspectivesTable 4Proposal for drug coding of "List of drugs to consider starting" ^1)^Therapeutic category/JAN English nameJapan ^2)^ATC ^2)^Antiparkinson drugs Combination (see Table [5](#Tab5){ref-type="table"})Vaccine: Influenza Influenza HA Vaccine (A/B)NAJ07BB02 Adsorbed Influenza Virus Vaccine (H5N1)NAJ07BB02Vaccine: Pneumococcal Pneumococcal Polysaccharide Conjugate Vaccine(adsorbed)631140GJ07AL52 Pneumococcus Vaccine6311400J07AL01Cardiovascular system: Angiotensin conversion enzyme (ACE) inhibitor Alacepril2144003C09AA Benazepril Hydrochloride2144007C09AA07 Captopril2144001C09AA01 Cilazapril Hydrate2144005C09AA08 Delapril Hydrochloride2144004C09AA12 Enalapril Maleate2144002C09AA02 Imidapril Hydrochloride2144008C09AA16 Lisinopril Hydrate2144006C09AA03 Perindopril Erbumine2144012C09AA04 Quinapril Hydrochloride2144010C09AA06 Temocapril Hydrochloride2144009C09AA14 Trandolapril2144011C09AA10Cardiovascular system: Angiotensin receptor blocker (ARB) Azilsartan2149048C09CA09 Candesartan Cilexetil2149040C09CA06 Irbesartan2149046C09CA04 Olmesartan Medoxomil2149044C09CA08 Telmisartan2149042C09CA07 Valsartan2149041C09CA03 Losartan Potassium2149039C09CA01 Coombination (See Table [5](#Tab5){ref-type="table"})Cardiovascular system: Lipid modifying agents (Statine) Atorvastatin Calcium Hydrate2189015C10AA05 Fluvastatin Sodium2189012C10AA04 Pitavastatin Calcium Hydrate2189016C10AA08 Pravastatin Sodium2189010C10AA03 Rosuvastatin Calcium2189017C10AA07 Simvastatin2189011C10AA01 Coombination (See Table [5](#Tab5){ref-type="table"})Urologicals: Drugs for benign prostatic hypertrophy (selective alpha-1 blockers) Naftopidil2590009G04CA Silodosin2590010G04CA04 Tamsulosin Hydrochloride2590008G04CA02Antineoplastic and immunomodulating agents: Drugs for rheumatoid arthritis Actarit1149031M01CX Auranofin4420001M01CB03 Bucillamine4420002M01CC02 Iguratimod3999031M01CX Leflunomide3999020L04AA13 Lobenzarit Sodium1149020M01CXMethotrexate4222001\
3999016L01BA01\
L04AX03 Mizoribine3999002L04AX Salazosulfapyridine6219001A07EC01 Tofacitinib Citrate3999034L04AA29ATC: Anatomical Therapeutic Chemical Classification SystemJAN: Japanese Accepted Names for Pharmaceuticals^1)^Drugs that had been previously approved but do not currently being marketed are excluded. The list includes long-term oral use drugs as a general rule, except self-injection insulin, according to the guidelines (Japan Geriatric Society. Guidelines for Medical Treatment and its Safety in the elderly 2015 (In Japanese). Toyko, Medical View Co., Ltd. 2015.)^2)^the first 7-digit numbers of the code of the Japanese drug price list.A different base adduct may or may not require different codes in Japan; hydroxyzine (1179005 for hydrochloride, 1179019 for pamoate) or promethazines (4413002).^3)^ATC codes for topical use were excluded, e.g. A07EA Corticosteroids acting locally, D04AA Antihistamines for topical use; defined daily dose (DDD) are not available for most of those.Table 5Proposal for coding the combination drugs of "List of drugs to be prescribed with special caution" and "List of drugs to consider starting"Combination drugs (substance name in JAN)Japan ^1)^ATC^2)^"List of drugs to be prescribed with special caution"Chlorpromazine Hydrochloride\
Phenobarbital \*\
Promethazine Hydrochloride1179100\
1179101R06AD52 promethazine, combinations or N05AA01 chlorpromazine and R06AD02 promethazinetia\
Aluminum Glycinate \*\
Magnesium Carbonate \*1143010\
3399100N02BA51 acetylsalicylic acid, combinations excl. PsycholepticsAcetylsalicylic acid (aspirin)\
Clopidogrel Sulfate3399101N02BA51 acetylsalicylic acid, combinations excl. Psycholeptics or B01AC06 acetylsalicylic acid and B01AC04 clopidogrelAcetylsalicylic acid (aspirin)\
Lansoprazole \*3399102B01AC56 acetylsalicylic acid, combinations with proton pump inhibitorsMetformin Hydrochloride\
Pioglitazone Hydrochloride3969100A10BD05 metformin and pioglitazoneGlimepiride\
Pioglitazone Hydrochloride3969101A10BD06 glimepiride and pioglitazoneMitiglinide\
Voglibose3969102A10BD Combinations of oral blood glucose lowering drugs or A10BX08 mitiglinide and A10BF03 voglibosePioglitazone\
Alogliptin\*3969103A10BD09 pioglitazone and alogliptinMetformin\
Vildagliptin\*3969104A10BD08 metformin and vildagliptinAlogliptin\*\
Metformin3969105A10BD13 metformin and alogliptin"List of drugs to consider starting"Entacapone \*\
Carbidopa Hydrate\
Levodopa1169102N04BA03 levodopa, decarboxylase inhibitor and COMT inhibitorCarbidopa Hydrate \*\
Levodopa1169101N04BA02 levodopa and decarboxylase inhibitorBenserazide Hydrochloride \*\
Levodopa1169100N04BA02 levodopa and decarboxylase inhibitorAzilsartan\
Amlodipine Besilate2149121C09CA09 azilsartan medoxomil and C08CA01 amlodipineAzelnidipine\
Olmesartan Medoxomil2149115C08C selective calcium channel blockers with mainly vascular effects and C09CA08 olmesartan medoxomilAmlodipine Besilate\
Irbesartan2149118C09DB05 irbesartan and amlodipineAmlodipine Besilate\
Candesartan Cilexetil2149116C09DB07 candesartan and amlodipineAmlodipine Besilate\
Telmisartan2149117C09DB04 telmisartan and amlodipineAmlodipine Besilate\
Valsartan2149114C09DB01 valsartan and amlodipineIrbesartan\
Trichlormethiazide2149119C09DA04 irbesartan and diureticsCandesartan Cilexetil\
Hydrochlorothiazide2149111C09DA06 candesartan and diureticsCilnidipine\
Valsartan2149120C08CA14 cilnidipine and C09CA03 valsartanTermisartan\
Hydrochlorothiazide2149113C09DA07 telmisartan and diureticsValsartan\
Hydrochlorothiazide2149112C09DA03 valsartan and diureticsHydrochlorothiazide\
Losartan Potassium2149110C09DA01 losartan and diureticsAtorvastatin Calcium Hydrate\
Amlodipine Besilate2190101\
2190102 2190103 2109104C10BX03 atorvastatin and amlodipineATC: Anatomical Therapeutic Chemical Classification SystemJAN: Japanese Accepted Names for Pharmaceuticals^1)^The first 7-digit numbers of the code of the Japanese drug price list. The drugs with a different compounding ratio of active substances need different codes in the National Health Insurance Drug Price Standard in Japan. For example, there are bland medicinal products with acetylsalicylic acid 330 mg for anti-inflammatory use (1143010) and 81 mg for antiplatelet (3399100)^2)^Some combination drugs have individual ATC codes\* Substances are excepted from the STOPP-J list (Table 3and 4)

Combination products were separately listed (Table [5](#Tab5){ref-type="table"}) and were divided into three groups, consisting of one where the combination of exact substances was found in the ATC, such as amlodipine besylate and irbesartan (C09DB05), the ATC representing combination such as levodopa and decarboxylase inhibitor (N04BA02), and another where each substance had an individual ATC. Among the constituent substances in the latter case, the ATCs were presented only for the JGS listed substances. For example, only aspirin was selected from BUFFERIN Combination Tablet® with aspirin, aluminum glycinate, and magnesium carbonate. If the combination product consisted of the same substances in different proportions, different codes were assigned by the price list. For example, combinations of atorvastatin calcium hydrate, and amlodipine besylate were coded 2190101, 2190102, 2190103, or 2109104, depending on their compounding ratio. In addition, drugs can be categorized differently in the Japanese pricing list and have several codes; for example, BUFFERIN Combination Tablet® is 1143010 as "antipyretics, analgesics, and anti-inflammatory agents" and 3399100 as "other agents relating to blood and body fluids" All codes are listed in the tables.

Discussion {#Sec6}
==========

Identification and application of STOPP-J drug substances {#Sec7}
---------------------------------------------------------

The efforts to reduce inappropriate drug use in elderly patients are likely to have a substantial impact on reducing drug-related morbidity. One major required step is a change in the prescription behavior of physicians, which is influenced by their knowledge and alert systems involving pharmacists, computerized reminders \[[@CR19]\], and promotional information from pharmaceutical companies \[[@CR20]\]. The current JGS guidelines provide concept and review steps for prescribing to the elderly but do not fully detail specific substances. Thus, our computerized database of standard drug substances, reflecting the STOPP-J with a corresponding coding system, will provide an efficient way to improve physician knowledge about medication for the elderly.

This study revealed that some substances approved in Japan were omitted from the ATC classification system, which was also reported by Groot et al. \[[@CR8]\] in reference to the STOPP/START. This may occur when a drug is marketed in Japan only, and the substance or combination is not registered with the WHO Collaborating Center for Drug Statistics. When other countries have the same situation, it would also be necessary to set up the framework to ask the WHO Collaboration Center to include medicinal substances limited to them. This would enhance ATC completeness. To support ATC users, the Uppsala Monitoring Center/WHO Collaborating Centre for International Drug Monitoring does provide the WHO Drug Global with drug information, including Japanese approved drugs and referencing ATC codes at the 5th level, for global pharmacovigilance \[[@CR21]\]. Their service supports linking Japanese substances with the ATC, and major global companies use this service for internal databases. It is important to make ATC codes useful in pharmacovigilance and pharmacoepidemiology studies for all Japanese and worldwide drugs and create an official framework to register new substance as soon as possible. This would facilitate drug safety monitoring by pharmaceutical companies and the review of drugs at the class and substance levels. We excluded some medicinal products from the first listing step of the drug indication categories. This paradoxically suggests that researchers run the risk of including appropriately prescribed drugs when extracting data from the drug classification systems.

When the Beers criteria were applied to studies on Japanese elderly patients, hospitalization risk was higher in potentially inappropriate medication users \[[@CR12]\] and, in contrast, no association was observed between potentially inappropriate medication use and adverse outcomes \[[@CR13]\]. The study using STOPP and START addressed the notion that potentially inappropriate prescribing increased healthcare utilization \[[@CR22]\]. Although some drug utilization studies have been reported on the STOPP-J, the future applications of our results to pharmacoepidemiologic clinical studies are worth considering in Japan, similar to a previous study using the Beers criteria in Japan \[[@CR12], [@CR13]\]. The use of large databases has become more sophisticated, and 13 Japanese healthcare databases are acknowledged by other entities \[[@CR23]\] (e.g., JMDC Claims Database® \[[@CR24]\], which provides the names and ATC codes of drugs prescribed from 2005). Some unlisted domestic databases also exist, including the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB), which maintain data records from April 2013 provided by the ministry \[[@CR25]\]. Currently, no ATC codes are available in the NDB, but the National Health Insurance Drug Price List codes are provided and, therefore, our proposed codes can be used. Another database is the Japanese Adverse Drug Event Report database (JADER), which records spontaneous reports of adverse events to the regulatory agency and lists drug names in plain text, without codes \[[@CR26]\]. MID-NET is another prospective database, which was launched in April 2018 by the regulatory agency \[[@CR27]\]. It is noteworthy that global comparisons based on the guidelines for medication in the elderly would be complicated or difficult to analyze because substances and their corresponding codes vary.

Currently, there are many therapeutic guidelines and principles for the proper use of medicines, and different definitions are presented worldwide or even in certain countries. Since those guidelines are to be updated periodically in several years, the guidelines propose their philosophies and examples, without identification of drugs. Therefore, interpretation and practice tend to vary by users. When adopting the guidelines, it is important to first define drugs of interest at the component molecule level; however, papers that do not identify the studied drug names might exist. In this research, with reference to the research method of Groot et al. \[[@CR8]\] of Ireland, we presented concrete pharmaceutical molecules intended by the STOPP-J proposed by the JGS and proposed corresponding drug codes to be widely used in Japan. The results of this research are expected to be helpful in designing research and validating the actual condition of medical service at a clinical institute. Another important application is to import the drug code list into electronic prescription systems and health information systems so that the system can aid physicians in prescribing cautiously. This application is expected to be used in practice in the near future.

Limitations of using the list {#Sec8}
-----------------------------

This study was limited to Japanese drugs for internal use, except insulin, because the JGS guidelines focus on the long-term use of drugs to promote appropriate medications and avoid systemic adverse events in the elderly. The study also excluded drugs mainly used for short-term treatments of less than 1 month, e.g., antipyretics. In addition, based on the JGS, the target population in our list comprised patients older than 75 years who are with or without frailty, which is quite different from other guidelines. The drug list would be useful in research to understand the status of drug prescribing or hypothesize about the trends in total drug use and polypharmacy. However, more information such as dosage regimens and comorbidities is normally required to answer clinical questions. Users also need to consider how to interpret the output. For example, the alerted drug should be able to be monitored or stopped for individual patients. Because the JGS tool is not meant to be a prescription rule, but rather provides information to support physicians' judgment when prescribing, the dosage regimen and underlying diseases should be mentioned. Lastly, a periodic update of the list is critical for efficient use in practice.

This was the first challenge to identify the STOPP-J substances to be coded. Some difficulties were found through the work in the interpretation of the STOPP-J, for example, insulins, and healthcare data users may misunderstand what the guidelines really proposed. In addition, new medicines need to be timely evaluated to determine whether they should be prescribed with special caution or considered for medication.

Conclusion {#Sec9}
==========

The STOPP-J drug list is proposed in this study as a starting point for discussion for researchers. Our consolidated lists can be used for pharmacoepidemiological database studies. Some WHO ATC codes were omitted owing to regionalized drug availability or combination drugs, which must be considered when using or interpreting the present data.
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